KMT2A and acute lymphoblastic leukemia: In children, midostaurin has been investigated as monotherapy in r/r pediatric leukemia, including KMT2A-rearranged ALL or FLT3-mutated AML (NCT0866281), which unfortunately demonstrated limited efficacy in the 22 enrolled participants (the trial terminated early due to lack of enrollment) [87].